 |
|
Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer
September 26, 2007Barcelona, Spain: Researchers in Portugal have discovered that a specific mutation of the COX2 gene seems to play a role in the onset of ovarian cancer, increasing women's susceptibility to developing the disease.
The discovery raises the possibility that, if the findings are confirmed by further studies, it might be possible to use non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, which are used already for other conditions, to prevent ovarian cancer developing in women with the COX2 mutation.
Dr Ana Carina Pereira told the European Cancer Conference (ECCO 14) in Barcelona, today (Tuesday) that the COX2 gene is responsible for the production of the enzyme COX-2, which plays a crucial role in prostaglandins production; prostaglandins cause inflammation, pain and fever, as well as mediating a wide range of other physiological processes. "Although the causes of ovarian cancer are not fully understood yet, inflammation is known to play an important role in the onset of both ovarian and invasive cervical cancer," she said. "COX-2 has an important role in the inflammatory process, as well as in key steps in tumour development."
Dr Pereira, who is a junior scientist in the molecular oncology group at the Portuguese Institute of Oncology, Oporto, Portugal, said that one mutation, the -765G>C COX2 polymorphism, had been associated with the development of a number of diseases such as cancers of the stomach, oesophagus and prostate, and asthma, heart attacks and stroke. So she and her colleagues decided to investigate the role it played in ovarian and invasive cervical cancer.
They analysed the DNA in blood samples from 727 women; 150 had ovarian cancer, 351 had cervical lesions, including 291 with cervical cancer, and the remaining 226 women had no cancer and were the control group.
Although they found no evidence that the -765G>C COX2 polymorphism played a role in cervical cancer, they found that particular versions of it doubled the risk of developing ovarian cancer and, in women aged 53 or younger, it trebled the risk.
Dr Pereira looked at the distribution and frequency of three different types (genotypes) of the -765G>C COX2 polymorphism: the GG, GC and CC genotypes. An individual genotype is composed of two distinct parts, the inherited sequences from the maternal and paternal genomes. Therefore, for every genotype, there are two copies of the sequence and these copies are called alleles. Alleles may be identical or different.
Dr Pereira explained: "The C and G are alleles that can be inherited, one from each parent. As everyone carries two alleles, their genotypes could be a CC, GC or GG genotype. The G allele is the most common, while the CC genotype is rare; therefore, it is usual to pool the GC and CC genotypes together and we call people with these genotypes C allele carriers.
"Our results demonstrated that C allele carriers had a nearly two-fold (1.8) increased risk of developing ovarian cancer. This was even more evident when we stratified our analysis into two groups based on the average age of the patients; the women aged 53 or under had a nearly three-fold (2.8) increased risk of developing ovarian cancer."
She said the polymorphism could enhance the expression of the COX2 gene, thereby inhibiting apoptosis (programmed cell death) and promoting tumour proliferation, metastasis and angiogenesis (the formation of new blood vessels needed to supply a growing tumour). The reason why the same effect was not observed in cervical cancer was probably due to the different causes of the two cancers.
"The biological mechanism involved in the carcinogenesis of different organs is not always similar. In the case of cervical cancer we know that the trigger mechanism is an oncogenic virus, HPV (human papillomavirus) and that in ovarian cancer, although not as clearly understood, inflammation and hormonal regulation are credited with playing a role in its development."
She continued: "Although our findings are very interesting and this polymorphism seems to play an important role in cancer development, these are only preliminary results which need to be confirmed with more complete studies, nor only in the Portuguese population but also in other populations.
"The interesting clue from these results is the importance of this COX-2 enzyme and the therapeutic drugs that may inhibit its activity (such as aspirin and other NSAIDs). Former studies involving NSAIDs and risk for ovarian cancer were not strongly conclusive because the individual variability in the response to preventive drugs was not taken into account. Now we need studies that will confirm whether giving NSAIDs to women with this polymorphism might be of value in both preventing and treating ovarian cancer.
"Identifying the molecular epidemiologic profile of individuals may open new windows for the development of preventive strategies and for the individualisation of therapies for patients. It would be possible to anticipate the patient's response to therapy, increasing treatment efficacy and decreasing the incidence of adverse reactions to drugs."
ECCO-the European CanCer Conference
Dr Pereira, who is a junior scientist in the molecular oncology group at the Portuguese Institute of Oncology, Oporto, Portugal, said that one mutation, the -765G>C COX2 polymorphism, had been associated with the development of a number of diseases such as cancers of the stomach, oesophagus and prostate, and asthma, heart attacks and stroke. So she and her colleagues decided to investigate the role it played in ovarian and invasive cervical cancer.
They analysed the DNA in blood samples from 727 women; 150 had ovarian cancer, 351 had cervical lesions, including 291 with cervical cancer, and the remaining 226 women had no cancer and were the control group.
Although they found no evidence that the -765G>C COX2 polymorphism played a role in cervical cancer, they found that particular versions of it doubled the risk of developing ovarian cancer and, in women aged 53 or younger, it trebled the risk.
Dr Pereira looked at the distribution and frequency of three different types (genotypes) of the -765G>C COX2 polymorphism: the GG, GC and CC genotypes. An individual genotype is composed of two distinct parts, the inherited sequences from the maternal and paternal genomes. Therefore, for every genotype, there are two copies of the sequence and these copies are called alleles. Alleles may be identical or different.
Dr Pereira explained: "The C and G are alleles that can be inherited, one from each parent. As everyone carries two alleles, their genotypes could be a CC, GC or GG genotype. The G allele is the most common, while the CC genotype is rare; therefore, it is usual to pool the GC and CC genotypes together and we call people with these genotypes C allele carriers.
"Our results demonstrated that C allele carriers had a nearly two-fold (1.8) increased risk of developing ovarian cancer. This was even more evident when we stratified our analysis into two groups based on the average age of the patients; the women aged 53 or under had a nearly three-fold (2.8) increased risk of developing ovarian cancer."
She said the polymorphism could enhance the expression of the COX2 gene, thereby inhibiting apoptosis (programmed cell death) and promoting tumour proliferation, metastasis and angiogenesis (the formation of new blood vessels needed to supply a growing tumour). The reason why the same effect was not observed in cervical cancer was probably due to the different causes of the two cancers.
"The biological mechanism involved in the carcinogenesis of different organs is not always similar. In the case of cervical cancer we know that the trigger mechanism is an oncogenic virus, HPV (human papillomavirus) and that in ovarian cancer, although not as clearly understood, inflammation and hormonal regulation are credited with playing a role in its development."
She continued: "Although our findings are very interesting and this polymorphism seems to play an important role in cancer development, these are only preliminary results which need to be confirmed with more complete studies, nor only in the Portuguese population but also in other populations.
"The interesting clue from these results is the importance of this COX-2 enzyme and the therapeutic drugs that may inhibit its activity (such as aspirin and other NSAIDs). Former studies involving NSAIDs and risk for ovarian cancer were not strongly conclusive because the individual variability in the response to preventive drugs was not taken into account. Now we need studies that will confirm whether giving NSAIDs to women with this polymorphism might be of value in both preventing and treating ovarian cancer.
"Identifying the molecular epidemiologic profile of individuals may open new windows for the development of preventive strategies and for the individualisation of therapies for patients. It would be possible to anticipate the patient's response to therapy, increasing treatment efficacy and decreasing the incidence of adverse reactions to drugs."
ECCO-the European CanCer Conference
COX2 Current Events and COX2 News RSSIs there any association between COX2 and colon cancer?
Non-steroidal anti-inflammatory drugs (NSAIDs), which are known to reduce the risk of colon cancer, act directly on cyclooxygenase-2 (COX2) and reduce its activity.
Genes found to play a role in breast cancer's spread to the brain
New research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs. The study was published online today in Nature.
A new century of Alzheimer's disease research
Imagine the day when a routine visit to the family doctor includes a simple blood test to predict the risk for developing Alzheimer's disease (AD).
A genetic 'gang of 4' drives spread of breast cancer
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
Genes set scene for metastasis
Biologists at Memorial Sloan-Kettering Cancer Center (MSKCC) have identified a set of genes expressed in human breast cancer cells that work together to remodel the network of blood vessels at the site of the primary tumor.
COX2 inhibitor could offer benefits over other anti-inflammatory drugs for osteoarthritis (pp 639, 665, 675)
Results of an international multi-centre study in this week's issue of THE LANCET suggest that the COX2 inhibitor lumiracoxib could be an effective treatment for osteoarthritis-its use was associated with an 80% reduction in gastric complications compared with other conventional anti-inflammatory drugs. The use of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) is widespread to reduce the pain associated with osteoarthritis; however the side-effects of these drugs can be severe, sometimes leading to gastro-intestinal ulcer complications which account for around 7000 US and 1000 UK deaths each year. The development of Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce t
New arthritis drugs less likely to cause side effects
A new group of arthritis drugs recommended by NICE for patients at risk of gastrointestinal complications may be safer than traditional drugs, research in this week's BMJ suggests. Claims that the drugs, known as selective COX2 inhibitors, caused fewer gastrointestinal problems than traditional arthritis drugs led to an increase in their use, but the research on which they were based was criticised. Two studies in this week's BMJ, however, show that the risk of gastrointestinal complications associated with selective COX 2 inhibitors is lower than that associated with conventional non-steroidal anti-inflammatory drugs (NSAIDs). In the first study researchers in Oxford reviewed all trials of
More COX2 Current Events and COX2 News Articles
 |
Why Does E=mc2?: (And Why Should We Care?) by Brian Cox (Author), Jeff Forshaw (Author) The most accessible, entertaining, and enlightening explanation of the best-known physics equation in the world, as rendered by two of today’s leading scientists. Professor Brian Cox and Professor Jeff Forshaw go on a journey to the frontier of 21st century science to consider the real meaning behind the iconic sequence of symbols that make up Einstein’s most famous equation, E=mc2. Breaking down the symbols themselves, they pose a series of questions: What is energy? What is mass? What has the speed of light got to do with energy and mass? In answering these questions, they take us to the site of one of the largest scientific experiments ever conducted. Lying beneath the city of Geneva, straddling the Franco-Swiss boarder, is a 27 km particle accelerator, known as the Large... |
 |
Blood Ties: Season Two Starring: Kyle Schmid, Dylan Neal, Christina Cox, Gina Holden, Françoise Yip Directed By: James Dunnison Blood Ties Season 2 picks up with Vicky Nelson and Henry Fitzroy being drawn into baffling cases involving a terrifying pantheon of occult adversaries. While Henry deals with Christina, the vampire from Henry s past who turned him into a Vampire 480 years ago. |
 |
Beautiful U R Jody den Broeder Club (Remix) Deborah Cox (Primary Contributor) |
 |
Absolute Heaven: Essential Choral Masterpieces Robert Shaw (Conductor), Atlanta Symphony Orchestra & Chorus (Conductor), Robert Shaw Festival Singers (Conductor) This sampler, which appeared in 1997, features Robert Shaw, the Atlanta Symphony Orchestra, and its associated choruses in selections from some of the choral-orchestral blockbusters they recorded for Telarc between 1979 and 1993, in consistently excellent sound. Shaw's unrivalled mastery of this repertory shines through in every selection on the disc, not least in the excerpts that frame the program: the final pages of the "Prologue in Heaven" from Boito's Mefistofele, and the towering conclusion of Mahler's Symphony No. 8, both magnificently done. Just one warning: after listening to this, you're likely to find yourself hurrying back to buy the recordings of the complete works. --Ted Libbey |
 |
COX MPD 50 ml. Twin Mini-Cartridges 1:1, 2:1, 4:1 & 10:1 Mix Ratios Manual Epoxy Applicator by COX North America |
 |
Genesis, Part 2 - September 13, 1956 Starring: Jennifer Runyon, Christian Van Dorn, John Allen Nelson, W.K. Stratton, Bruce McGill Directed By: David Hemmings Also With: Donald P. Bellisario (Producer), Donald P. Bellisario (Writer) |
 |
COX 7F1015 2-Gallon Follower Plate by COX North America |
 |
Inflama-Rest COX-2 Inhibitor 90 tabs by SOURCE NATURALS Inflama-Rest is a Bio-Aligned formula that may ease joint function and support comfortable movement via inhibition of the COX-2 enzyme. It also addresses additional factors shown in scientific research to influence muscle and joint comfort: nuclear factor-kappa B activity, leukotriene regulation and nitric oxide production. Inflama-Rest helps to protect cells from free radical damage. It is specially formulated with adaptogenic herbs and minerals that may help reduce muscle tension associated with physical and emotional stress. * Picture may be of different size or flavor |
 |
Healthy Aging Nutraceuticals Cox-2 Support W/ Nexrutine-Ginger- Tumeric-Proteolitic Enzymes 180 Capsules by Healthy Aging Nutraceuticals Helps normalize inflammatory processes using the key ingredients w/Nexrutine, Ginger, Turmeric & proteolytic e. |
 |
Cox Reels EZ-SH-450 1/2" 50ft Air/water Safety Series Ezcoil Reel by Cox Reels Safety Series Hose Reels Style: Spring Retractable HoseIncluded (Yes/No): Yes Hose Length: 50 Inside Diameter: 1/2 Maximum Working Pressure (psi): 300 Material: Brass |
| © 2009 BrightSurf.com |